Latest Safety News

AVADA Group lifted revenue by nearly 15% in FY26, driven by Queensland and New South Wales expansion, while managing a $15 million impairment in Victoria that kept the statutory loss steady.

Liontown Limited (ASX:LTR) has reported its maiden profit and strong cash flow in FY26, completing its transition to fully underground mining at Kathleen Valley and advancing expansion plans with a final investment decision due early FY27.

SSH Group delivered a 23% revenue increase and 79% profit rise in FY26, fueled by the strategic acquisition of Elphinstone Mechanical Services and strengthened partnerships.

RemSense Technologies reported a 27% revenue decline in FY2026 to $2.49 million due to project timing and economic uncertainty but secured major Tier-1 contracts and raised $1.21 million to fund technology development.

PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.

Clime Capital Limited (ASX:CAM) reported a sharp turnaround for FY26, with net profit after tax soaring 236% to $10.29 million, driven by strong unrealised gains and a higher income portfolio. The company sustained its steady dividend payments and pressed ahead with an active share and convertible note buyback program.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

Foresta Group Holdings reports a doubling of its net loss to $6.8 million for FY2026 amid steady progress on its Kawerau biomass facility, highlighted by a long-term lease and key technical studies.

Berkeley Energia reported a $8.7 million net loss for FY2026 while pushing forward with its Salamanca uranium project and maiden critical minerals resource at Conchas. The company continues a $1.25 billion ICSID arbitration claim against Spain over permitting delays.